Sanofi Company Profile
What is the competitive landscape for SANOFI
SANOFI has one hundred and twenty-four approved drugs.
There are eleven US patents protecting SANOFI drugs.
Summary for Sanofi
| US Patents: | 11 |
| Tradenames: | 99 |
| Ingredients: | 89 |
| NDAs: | 124 |
| Patent Litigation for Sanofi: | See patent lawsuits for Sanofi |
| PTAB Cases with Sanofi as petitioner: | See PTAB cases with Sanofi as petitioner |
Drugs and US Patents for Sanofi
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | FERRLECIT | sodium ferric gluconate complex | INJECTABLE;INJECTION | 020955-001 | Feb 18, 1999 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sanofi Aventis Us | JEVTANA KIT | cabazitaxel | SOLUTION;INTRAVENOUS | 201023-001 | Jun 17, 2010 | AP | RX | Yes | Yes | 8,927,592*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Sanofi Aventis Us | BRONKODYL | theophylline | CAPSULE;ORAL | 085264-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sanofi
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | TORNALATE | bitolterol mesylate | SOLUTION;INHALATION | 019548-001 | Feb 19, 1992 | 4,138,581 | ⤷ Start Trial |
| Sanofi Aventis Us | DIABETA | glyburide | TABLET;ORAL | 017532-001 | May 1, 1984 | 4,060,634 | ⤷ Start Trial |
| Sanofi Aventis Us | NEGGRAM | nalidixic acid | SUSPENSION;ORAL | 017430-001 | Approved Prior to Jan 1, 1982 | 4,105,659 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SANOFI drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 75 mg, 150 mg and 300 mg | ➤ Subscribe | 2004-05-25 |
| ➤ Subscribe | Capsules | 0.5 mcg and 2.5 mcg | ➤ Subscribe | 2009-03-25 |
| ➤ Subscribe | Tablets | 300 mg | ➤ Subscribe | 2009-03-04 |
| ➤ Subscribe | Capsules | 1 mcg | ➤ Subscribe | 2010-02-12 |
| ➤ Subscribe | Tablets | 800 mg | ➤ Subscribe | 2008-12-04 |
| ➤ Subscribe | Injection | 40 mg/mL, 0.5 mL and 2 mL vials | ➤ Subscribe | 2009-06-30 |
| ➤ Subscribe | For Injection | 50 mg/vial and 100 mg/vial | ➤ Subscribe | 2007-02-09 |
| ➤ Subscribe | Injection | 5 mg/mL, 40 mL vial | ➤ Subscribe | 2011-03-23 |
| ➤ Subscribe | Tablets | 7 mg and 14 mg | ➤ Subscribe | 2016-09-12 |
| ➤ Subscribe | Tablets | 300 mg/25 mg | ➤ Subscribe | 2006-06-06 |
| ➤ Subscribe | Capsules | 0.4 mg | ➤ Subscribe | 2004-12-20 |
| ➤ Subscribe | Tablets | 400 mg | ➤ Subscribe | 2013-07-01 |
| ➤ Subscribe | Injection | 2 mcg/mL, 2 mL ampules | ➤ Subscribe | 2007-10-15 |
| ➤ Subscribe | Injection | 2 mcg/mL, 1 mL in 2 mL vial | ➤ Subscribe | 2011-12-28 |
| ➤ Subscribe | Powder for Oral Suspension | 0.8 g/packet and 2.4 g/packet | ➤ Subscribe | 2009-12-30 |
| ➤ Subscribe | Injection | 5 mg/mL, 10 mL and 20 mL vials | ➤ Subscribe | 2007-02-09 |
| ➤ Subscribe | Injection | 200 mg/40 mL | ➤ Subscribe | 2007-07-16 |
| ➤ Subscribe | Injection | 100 mg/mL, 3 mL vials | ➤ Subscribe | 2006-12-07 |
| ➤ Subscribe | Tablets | 150 mg/12.5 mg and 300 mg/12.5 mg | ➤ Subscribe | 2004-11-10 |
International Patents for Sanofi Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Peru | 20091809 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2011051894 | ⤷ Start Trial |
| European Patent Office | 2280701 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sanofi Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1667986 | C01667986/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: CABAZITAXELUM; REGISTRATION NO/DATE: SWISSMEDIC 61543 06.04.2011 |
| 1948158 | 1690020-1 | Sweden | ⤷ Start Trial | PRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123 |
| 0806968 | SPC/GB07/011 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
